Last reviewed 2026-04-23 · How we verify

ABT-530

ABT-530 is a selective inhibitor of the chemokine receptor CCR2 that reduces inflammatory monocyte recruitment to sites of inflammation.

ABT-530 is a selective inhibitor of the chemokine receptor CCR2 that reduces inflammatory monocyte recruitment to sites of inflammation. Used for Inflammatory conditions (Phase 2 development).

At a glance

Mechanism of action

CCR2 is a G-protein coupled receptor expressed on monocytes and other immune cells that mediates their migration in response to chemokine signals. By blocking CCR2, ABT-530 reduces the infiltration of pro-inflammatory monocytes into inflamed tissues, thereby dampening inflammatory responses. This mechanism is being explored in conditions characterized by excessive monocyte-driven inflammation.

Approved indications

• Inflammatory conditions (Phase 2 development)

Common side effects

No common side effects on file.

Key clinical trials

• Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) (PHASE3)
• A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (PHASE2, PHASE3)
• Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (PHASE3)
• A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (PHASE3)
• A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (PHASE3)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (PHASE2, PHASE3)
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (PHASE3)
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.